Cargando…

Variability of Findings in Drug-Induced Immune Haemolytic Anaemia: Experience over 20 Years in a Single Centre

BACKGROUND: Drug-induced immune haemolytic anaemia (DIHA) is difficult to diagnose, and its true incidence remains obscure. Here, we present cases of DIHA identified at our institute over the last two decades. METHODS: Serological tests were performed according to standard procedures. Detection of d...

Descripción completa

Detalles Bibliográficos
Autores principales: Mayer, Beate, Bartolmäs, Thilo, Yürek, Salih, Salama, Abdulgabar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4678312/
https://www.ncbi.nlm.nih.gov/pubmed/26696803
http://dx.doi.org/10.1159/000440673
_version_ 1782405433574555648
author Mayer, Beate
Bartolmäs, Thilo
Yürek, Salih
Salama, Abdulgabar
author_facet Mayer, Beate
Bartolmäs, Thilo
Yürek, Salih
Salama, Abdulgabar
author_sort Mayer, Beate
collection PubMed
description BACKGROUND: Drug-induced immune haemolytic anaemia (DIHA) is difficult to diagnose, and its true incidence remains obscure. Here, we present cases of DIHA identified at our institute over the last two decades. METHODS: Serological tests were performed according to standard procedures. Detection of drug-dependent antibodies was performed in the presence and absence of the relevant drug and/or their ex vivo antigens. RESULTS: Over the last 20 years, 73 patients have been identified with DIHA in our institute, which was related to 15 different drugs. The most common single drugs identified were diclofenac (n = 23), piperacillin (n = 13), ceftriaxone (n = 12) and oxaliplatin (n = 10). As far as data were available, haemolysis was acute in all patients, and signs of intravascular haemolysis were present in 90% of the cases. Haemolysis resulted in death in 17 patients (23%). The remaining patients recovered, but haemolysis was complicated by transitory renal and/or liver failure or shock in 11 patients. Upon initial evaluation, the antibody screening test was positive in 36 cases. A positive direct antiglobulin test (DAT) at least with anti-C3d was found in 65 cases, with anti-IgG only in 6 cases, and with anti-IgA only in 1 case. CONCLUSION: DIHA is a rare but potentially life-threatening disorder that should be considered if a patient develops haemolysis under drug treatment. The main serological finding is a positive DAT, primarily with anti-C3d.
format Online
Article
Text
id pubmed-4678312
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-46783122015-12-22 Variability of Findings in Drug-Induced Immune Haemolytic Anaemia: Experience over 20 Years in a Single Centre Mayer, Beate Bartolmäs, Thilo Yürek, Salih Salama, Abdulgabar Transfus Med Hemother Original Article BACKGROUND: Drug-induced immune haemolytic anaemia (DIHA) is difficult to diagnose, and its true incidence remains obscure. Here, we present cases of DIHA identified at our institute over the last two decades. METHODS: Serological tests were performed according to standard procedures. Detection of drug-dependent antibodies was performed in the presence and absence of the relevant drug and/or their ex vivo antigens. RESULTS: Over the last 20 years, 73 patients have been identified with DIHA in our institute, which was related to 15 different drugs. The most common single drugs identified were diclofenac (n = 23), piperacillin (n = 13), ceftriaxone (n = 12) and oxaliplatin (n = 10). As far as data were available, haemolysis was acute in all patients, and signs of intravascular haemolysis were present in 90% of the cases. Haemolysis resulted in death in 17 patients (23%). The remaining patients recovered, but haemolysis was complicated by transitory renal and/or liver failure or shock in 11 patients. Upon initial evaluation, the antibody screening test was positive in 36 cases. A positive direct antiglobulin test (DAT) at least with anti-C3d was found in 65 cases, with anti-IgG only in 6 cases, and with anti-IgA only in 1 case. CONCLUSION: DIHA is a rare but potentially life-threatening disorder that should be considered if a patient develops haemolysis under drug treatment. The main serological finding is a positive DAT, primarily with anti-C3d. S. Karger AG 2015-09 2015-09-09 /pmc/articles/PMC4678312/ /pubmed/26696803 http://dx.doi.org/10.1159/000440673 Text en Copyright © 2015 by S. Karger GmbH, Freiburg http://www.karger.com/Authors_Choice This is an open access article distributed under the terms of Karger's Author's Choice™ licensing agreement, adapted from the Creative Commons Attribution Non-Commercial 2.5 license. This license allows authors to re-use their articles for educational and research purposes as long as the author and the journal are fully acknowledged.
spellingShingle Original Article
Mayer, Beate
Bartolmäs, Thilo
Yürek, Salih
Salama, Abdulgabar
Variability of Findings in Drug-Induced Immune Haemolytic Anaemia: Experience over 20 Years in a Single Centre
title Variability of Findings in Drug-Induced Immune Haemolytic Anaemia: Experience over 20 Years in a Single Centre
title_full Variability of Findings in Drug-Induced Immune Haemolytic Anaemia: Experience over 20 Years in a Single Centre
title_fullStr Variability of Findings in Drug-Induced Immune Haemolytic Anaemia: Experience over 20 Years in a Single Centre
title_full_unstemmed Variability of Findings in Drug-Induced Immune Haemolytic Anaemia: Experience over 20 Years in a Single Centre
title_short Variability of Findings in Drug-Induced Immune Haemolytic Anaemia: Experience over 20 Years in a Single Centre
title_sort variability of findings in drug-induced immune haemolytic anaemia: experience over 20 years in a single centre
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4678312/
https://www.ncbi.nlm.nih.gov/pubmed/26696803
http://dx.doi.org/10.1159/000440673
work_keys_str_mv AT mayerbeate variabilityoffindingsindruginducedimmunehaemolyticanaemiaexperienceover20yearsinasinglecentre
AT bartolmasthilo variabilityoffindingsindruginducedimmunehaemolyticanaemiaexperienceover20yearsinasinglecentre
AT yureksalih variabilityoffindingsindruginducedimmunehaemolyticanaemiaexperienceover20yearsinasinglecentre
AT salamaabdulgabar variabilityoffindingsindruginducedimmunehaemolyticanaemiaexperienceover20yearsinasinglecentre